Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Amortization of Deferred Charges (2019 - 2025)

Historic Amortization of Deferred Charges for Conmed (CNMD) over the last 7 years, with Q4 2025 value amounting to $14.8 million.

  • Conmed's Amortization of Deferred Charges rose 707.61% to $14.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $57.1 million, marking a year-over-year increase of 341.35%. This contributed to the annual value of $57.1 million for FY2025, which is 341.35% up from last year.
  • Conmed's Amortization of Deferred Charges amounted to $14.8 million in Q4 2025, which was up 707.61% from $14.2 million recorded in Q3 2025.
  • Over the past 5 years, Conmed's Amortization of Deferred Charges peaked at $14.8 million during Q4 2025, and registered a low of $12.8 million during Q1 2022.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $13.8 million (2021), whereas its average is $13.8 million.
  • Per our database at Business Quant, Conmed's Amortization of Deferred Charges plummeted by 532.58% in 2022 and then soared by 842.25% in 2023.
  • Quarter analysis of 5 years shows Conmed's Amortization of Deferred Charges stood at $13.5 million in 2021, then increased by 1.54% to $13.7 million in 2022, then grew by 1.75% to $14.0 million in 2023, then decreased by 1.03% to $13.8 million in 2024, then grew by 7.08% to $14.8 million in 2025.
  • Its last three reported values are $14.8 million in Q4 2025, $14.2 million for Q3 2025, and $14.1 million during Q2 2025.